Stock Ratings / Health Care / PHAT / financials

MPLT (35) OVID (40) AQST (18) CTMX (14) ⌘ Pro Terminal →

Phathom Pharmaceuticals Inc. (PHAT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.74 -7.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.65

Phathom Pharmaceuticals Inc. (PHAT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $503.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PHAT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PHAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $5.74 (-7.72% 1D, market cap $503.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PHAT ranks #710 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PHAT compare to MPLT and OVID in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHAT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 87.1%, and ROIC of -35.0%. By comparison, MPLT (MapLight Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -32.4%, cap $500.1M) and OVID (Ovid Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -28.5%, cap $500.0M). Among the 5-stock peer group, PHAT leads on earnings multiple (N/A) while CTMX leads on capital efficiency (-20.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PHAT?

▼

Per PHAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001783183), Phathom Pharmaceuticals Inc. generated $175.1M in revenue (+216.9% YoY), -$221.3K in net income, and -$167.0M in free cash flow against $259.1M in total assets and $209.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.65 (-1.58%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHAT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY PHAT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 87.1% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$7.13-1.7% Next Q

Q2 (-2Q)

Grade E$7.01-15.3% Next Q

Q3 (-1Q)

Grade E$5.94-3.4% Next Q

Current

Grade E$5.74-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PHAT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PHAT currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.59) and Max Pain ($6.03) forces dealer call-delta covering toward $19.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PHAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PHAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PHAT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $682.0K

FY24

Rev $55.3M

FY25

Rev $175.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$175.1M	87.1%	-80%	-$221.3K	-$167.0M	-45%
FY 2024	$55.3M	85.6%	-80%	-$334.3K	-$266.9M	-45%
FY 2023	$682.0K	87.1%	-80%	-$201.6K	-$137.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PHAT)

✓Walkthrough of PHAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PHAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.40%▼ DESCENDING CHANNEL

2026-11-02O $6.28H $6.28L $5.74C $5.74VOL 3.84M

RES: $6.82SUP: $4.56SMA50: $7.59SMA200: $10.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PHAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PHAT Butterfly Map → + Track PHAT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PHAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PHAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PHAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHAT)

Health Care Rank #710 of 1016 ⚔️ MPLT vs PHAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PHAT vs. MPLT, OVID, AQST, CTMX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Phathom Pharmaceuticals Inc. (PHAT) ranks #710 by composite RQD confidence (34/100, grade E) and #450 by equity capitalization ($503.2M). Within this direct 5-issuer industry benchmark cohort, PHAT leads on earnings valuation at N/A trailing P/E, while CTMX leads on capital efficiency and profitability with -20.5% ROIC and — gross margin. OVID currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with PHAT at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PHAT ACTIVE Phathom Pharmaceuticals Inc.	E	34/100	—	87.1%	-35.0%	-7.72%	$503.2M	Benchmark Subject
MPLT MapLight Therapeutics Inc.	D-	35/100	—	—	-32.4%	-1.81%	$500.1M	/mplt-vs-phat →
OVID Ovid Therapeutics Inc.	D-	40/100	—	—	-28.5%	-0.78%	$500.0M	/ovid-vs-phat →
AQST Aquestive Therapeutics Inc.	E	18/100	—	58.3%	-35.0%	-3.71%	$507.1M	/aqst-vs-phat →
CTMX CytomX Therapeutics Inc.	E	14/100	—	—	-20.5%	+2.18%	$499.0M	/ctmx-vs-phat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001783183

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Phathom Pharmaceuticals Inc. (PHAT) reported GAAP revenue of $175.1M (+216.9% vs. FY2024 revenue of $55.3M , and +25576.0% cumulative change since FY2023) , GAAP net income of -$221.3K, operating cash flow of -$166.8M, and free cash flow of -$167.0M (+37.4% YoY). On the balance sheet, PHAT closed FY2025 with $259.1M in total assets against $209.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$175.1M	-$221.3K	-$166.8M	-$167.0M	$259.1M	$209.1M
FY2024 (FY)	2024-12-31	$55.3M	-$334.3K	-$266.8M	-$266.9M	$378.3M	$201.4M
FY2023 (FY)	2023-12-31	$682.0K	-$201.6K	-$137.6M	-$137.6M	—	—

3. PHAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PHAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PHAT compare to MPLT and OVID in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PHAT?

Where is PHAT trading relative to its 50-day, 200-day, and 52-week technical levels?

PHAT last traded at $5.74 (-7.72% on volume of 1,620,589 shares), positioning the stock -24.37% below its 50-day simple moving average ($7.59) and -44.81% below its 200-day simple moving average ($10.40). Across its 52-week range of $5.01 to $18.31, PHAT sits at the 5.5% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.02 to $6.46).

PHAT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Phathom Pharmaceuticals Inc. (PHAT)?

In FY 2025 (10-K), PHAT converted $175.1M of revenue into a 87.1% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PHAT RQD Cockpit PHAT 12M Forecast PHAT Earnings & Move PHAT Dividends & DRIP PHAT Insiders & 13F PHAT Whale Options PHAT Profit Sankey PHAT News & Why

Sector Peer Dials

Compare →

MPLT D-

MapLight Therapeutics Inc.

35 /100

OVID D-

Ovid Therapeutics Inc.

40 /100

AQST E

Aquestive Therapeutics Inc.

18 /100

CTMX E

CytomX Therapeutics Inc.

PHAT Core Snapshot

Market Cap $503.2M

Trailing / Fwd P/E — / —

Gross Profit Margin 87.1%

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $5.12

FREE TRADER TOOLS

Own PHAT Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With PHAT → 🏆 Trade PHAT in $100K Prop Arena →

PHAT Wire

Why It Moved →

Direct Company Event Yahoo Finance • 8h ago

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates

Direct Company Event StockInvest.us • 11h ago

Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT?

Direct Company Event Stocktwits • 14h ago

Phathom Pharmaceuticals Inc (PHAT) Earnings, Actual EPS, EPS Estimates & Results

Direct Company Event www.debelegger.nl • 17h ago

Phathom Pharmaceuticals (PHAT) Stock Price, Chart & Analysis

Direct Company Event TradingView • 20h ago

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PHAT — Phathom Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:35:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PHAT scores 34 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow scores 4/20 (institutional accumulation and options positioning), Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 7/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 11/20 (Altman Z 2.5; Piotroski F 4/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars cluster around cash generation and ownership signals. A 0% FCF yield and -35% ROIC mean the rating does not credit the business with current cash-based valuation support, so any upside would need to come from future cash generation that the source data does not yet show. The institutional and insider pillars score low, meaning the rating observes limited smart-money conviction. The Forensic Balance Sheet pillar is the relatively stronger component, supported by an Altman Z of 2.5 and a Debt/Equity of 0.5, but a Piotroski F of 4/9 signals only modest financial strength. Upside drivers would have to come from a reversal in operating losses; valuation tradeoffs are difficult to assess because forward and trailing earnings multiples are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$175.1M	$-160.0M	$-0.2M	N/A	$-167.0M	$130.0M	$209.1M
FY 2024	$55.3M	$-277.5M	$-0.3M	N/A	$-266.9M	$297.3M	$201.4M
FY 2023	$0.7M	$-167.3M	$-0.2M	N/A	$-137.6M	N/A	N/A

Per the SEC financials, operating income was negative in each reported period, and the market data shows an operating margin of -60% and a net margin of -0.1%. Per the market data, ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9, both per the Roarable RQD rating. Debt/Equity is 0.5 per the same source; cash declined from $297.3M in FY 2024 to $130.0M in FY 2025 while debt rose from $201.4M to $209.1M.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, five items reference PHAT. The most recent is a headline stating that Phathom Pharmaceuticals lagged Q3 earnings and revenue estimates, tagged as a market wire item. The source notes a results webcast beginning at 8 a.m. on Oct. 29, with a recording available for 90 days, tagged as a catalyst and flagged GREEN. The remaining items are market-wire summaries of price forecasts, EPS results, chart analysis, and an earnings call recap. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present.

Open Questions

What specific products or revenue sources drive the FY 2025 revenue of $175.1M relative to FY 2024 revenue of $55.3M?
What explains the gap between an operating loss of $-160.0M and a net income of $-0.2M in FY 2025?
What are the trailing and forward earnings multiples, given that P/E and EPS are unavailable in source data?
What is the company's debt maturity schedule and funding runway, given cash fell to $130.0M against $209.1M of debt?
What is the basis for the 52-week trading range of $5.01 to $18.31 relative to the current price of 6.22?

PHAT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Phathom Pharmaceuticals Inc. (PHAT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PHAT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 8h ago

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates

Yahoo Finance report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 11h ago

Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT?

StockInvest.us report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 14h ago

Phathom Pharmaceuticals Inc (PHAT) Earnings, Actual EPS, EPS Estimates & Results

Stocktwits report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.debelegger.nl • 17h ago

Phathom Pharmaceuticals (PHAT) Stock Price, Chart & Analysis

www.debelegger.nl report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 20h ago

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

TradingView report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 23h ago

At 8 a.m. Oct. 29, Phathom's results webcast begins; a recording will be available for 90 days.

Stock Titan report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

Phathom Pharmaceuticals (PHAT) Stock Price Drops After Q3 Earnings Growth

Simply Wall St report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Kalkine • 1d ago

Phathom Pharmaceuticals (NASDAQ:PHAT) Reports 71% Revenue Growth in Q3 2026

Kalkine report covering Phathom Pharmaceuticals Inc. (PHAT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PHAT Bull vs. Bear Conversation Board — What's Your Call at $5.74?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PHAT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.47 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PHAT (E • RQD 34/100) a Buy at $6.22?

Welcome to the PHAT (Phathom Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.10 (-18.0%)

Spot @ $6.22

Pump the brakes on PHAT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PHAT, but look at what you are paying: current EV/EBITDA multiples with 87.1% gross margins. Unless Phathom Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.22 (+16.1%)

Spot @ $6.22

PHAT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PHAT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.22 (52-wk range $5.01 - $18.31), any beat on forward guidance forces shorts and underweight funds to chase.